We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » House Lawmakers Probe for More Details of FDA’s Aduhelm Approval
House Lawmakers Probe for More Details of FDA’s Aduhelm Approval
The outcry over the FDA’s June 7 accelerated approval of Biogen’s Alzheimer’s drug Aduhelm gained new momentum last week as two House committees demanded more details from the FDA by Sept. 16 about the circumstances that led up the controversial decision.